“So I can tell you that all of our partner programs move forward. And, um, they are delighted with our science. I can also tell you that our partners are going through… all of them are going through their strategic reviews. Novartis is changed the head of NIBR, uh Biogen has changed their CEO, and so we’re always interested to watch what happens with those programs. It’s their strategy, it’s their decision to take forward. I’m very clear that when we partner, we partner and get the upfront, and when we get an upfront it funds the company. Since I’ve taken over SGMO we’ve raised $1.6B, of which $800M is from upfront. And when you take that you lose decision rights because it’s the other company’s. But we make sure with very close alignment that they’re progressing those, and so those assets are moving forward. And they’re increasing in value and increasing in importance.”
-Sandy Macrae, March 15, 2023, Barclay’s Global Healthcare Conference, Miami
“On March 13, 2023, Novartis Institutes for BioMedical Research, Inc. (“Novartis”) notified Sangamo Therapeutics, Inc. (“Sangamo”) of its termination for convenience, effective June 11, 2023 (the “Novartis Termination Date”), of the Collaboration and License Agreement (the “Novartis Agreement”) by and between Novartis and Sangamo dated July 27, 2020, pursuant to which Novartis and Sangamo were engaged in programs to research gene regulation therapies to treat three neurodevelopment disorders.”
“On March 17, 2023, Biogen MA, Inc. and its affiliate, Biogen International GmbH (together, “Biogen”) notified Sangamo of its termination for convenience, effective June 15, 2023 (the “Biogen Termination Date”), of the Collaboration and License Agreement (the “Biogen Agreement”) by and between Biogen and Sangamo dated February 26, 2020, pursuant to which Biogen and Sangamo were engaged in programs to research and develop gene regulation therapies to treat neurological diseases.”
-Sangamo 8-K, released March 17, 2023